Pharmacokinetic Analysis of the Bioavailability of AQUATURM®, a Water-Soluble Curcumin Formulation, in Comparison to a Conventional Curcumin Tablet, in Human Subjects
Background/Objectives: Curcumin, the principal bioactive component of Curcuma longa, is known for its anti-inflammatory, antioxidant, and neuroprotective properties. Despite its therapeutic potential, curcumin exhibits poor oral bioavailability due to low solubility, rapid metabolism, and limited ga...
Uloženo v:
| Vydáno v: | Pharmaceuticals (Basel, Switzerland) Ročník 18; číslo 7; s. 1073 |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Switzerland
MDPI AG
21.07.2025
MDPI |
| Témata: | |
| ISSN: | 1424-8247, 1424-8247 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Background/Objectives: Curcumin, the principal bioactive component of Curcuma longa, is known for its anti-inflammatory, antioxidant, and neuroprotective properties. Despite its therapeutic potential, curcumin exhibits poor oral bioavailability due to low solubility, rapid metabolism, and limited gastrointestinal absorption. Various delivery systems have been developed to overcome these limitations. This study aimed to evaluate and compare the pharmacokinetic profile of AQUATURM®, a novel, water-soluble curcumin formulation, with that of a widely available commercial curcumin supplement. Methods: A randomized, double-blind, two-period crossover study was conducted in 12 healthy adult participants (6 male, 6 female; aged 20–45 years). Each participant received a single oral dose of either AQUATURM® or the comparator product, followed by a 7-day washout period before receiving the alternate treatment. Blood samples were collected at multiple time points over a 12-h period post-dosing. Plasma curcumin concentrations were quantified using ultra-performance liquid chromatography with tandem mass spectrometry (UPLC-MS/MS). Results: AQUATURM® achieved a significantly higher systemic exposure compared to the comparator, with a more than 7-fold increase in area under the curve (AUC0–12h) and higher peak plasma concentrations (Cmax). AQUATURM® also maintained detectable curcumin levels for the full 12-h observation period, whereas levels from the comparator fell below quantification limits in most participants after 4 h. Conclusions: AQUATURM® significantly enhances curcumin bioavailability in humans compared to a standard curcumin formulation. These pharmacokinetic improvements support its potential for greater clinical efficacy and warrant further evaluation in therapeutic setting |
|---|---|
| AbstractList | Background/Objectives: Curcumin, the principal bioactive component of Curcuma longa, is known for its anti-inflammatory, antioxidant, and neuroprotective properties. Despite its therapeutic potential, curcumin exhibits poor oral bioavailability due to low solubility, rapid metabolism, and limited gastrointestinal absorption. Various delivery systems have been developed to overcome these limitations. This study aimed to evaluate and compare the pharmacokinetic profile of AQUATURM®, a novel, water-soluble curcumin formulation, with that of a widely available commercial curcumin supplement. Methods: A randomized, double-blind, two-period crossover study was conducted in 12 healthy adult participants (6 male, 6 female; aged 20–45 years). Each participant received a single oral dose of either AQUATURM® or the comparator product, followed by a 7-day washout period before receiving the alternate treatment. Blood samples were collected at multiple time points over a 12-h period post-dosing. Plasma curcumin concentrations were quantified using ultra-performance liquid chromatography with tandem mass spectrometry (UPLC-MS/MS). Results: AQUATURM® achieved a significantly higher systemic exposure compared to the comparator, with a more than 7-fold increase in area under the curve (AUC[sub.0–12] h) and higher peak plasma concentrations (Cmax). AQUATURM® also maintained detectable curcumin levels for the full 12-h observation period, whereas levels from the comparator fell below quantification limits in most participants after 4 h. Conclusions: AQUATURM® significantly enhances curcumin bioavailability in humans compared to a standard curcumin formulation. These pharmacokinetic improvements support its potential for greater clinical efficacy and warrant further evaluation in therapeutic setting Background/Objectives: Curcumin, the principal bioactive component of Curcuma longa, is known for its anti-inflammatory, antioxidant, and neuroprotective properties. Despite its therapeutic potential, curcumin exhibits poor oral bioavailability due to low solubility, rapid metabolism, and limited gastrointestinal absorption. Various delivery systems have been developed to overcome these limitations. This study aimed to evaluate and compare the pharmacokinetic profile of AQUATURM®, a novel, water-soluble curcumin formulation, with that of a widely available commercial curcumin supplement. Methods: A randomized, double-blind, two-period crossover study was conducted in 12 healthy adult participants (6 male, 6 female; aged 20–45 years). Each participant received a single oral dose of either AQUATURM® or the comparator product, followed by a 7-day washout period before receiving the alternate treatment. Blood samples were collected at multiple time points over a 12-h period post-dosing. Plasma curcumin concentrations were quantified using ultra-performance liquid chromatography with tandem mass spectrometry (UPLC-MS/MS). Results: AQUATURM® achieved a significantly higher systemic exposure compared to the comparator, with a more than 7-fold increase in area under the curve (AUC0–12h) and higher peak plasma concentrations (Cmax). AQUATURM® also maintained detectable curcumin levels for the full 12-h observation period, whereas levels from the comparator fell below quantification limits in most participants after 4 h. Conclusions: AQUATURM® significantly enhances curcumin bioavailability in humans compared to a standard curcumin formulation. These pharmacokinetic improvements support its potential for greater clinical efficacy and warrant further evaluation in therapeutic setting Background/Objectives: Curcumin, the principal bioactive component of Curcuma longa, is known for its anti-inflammatory, antioxidant, and neuroprotective properties. Despite its therapeutic potential, curcumin exhibits poor oral bioavailability due to low solubility, rapid metabolism, and limited gastrointestinal absorption. Various delivery systems have been developed to overcome these limitations. This study aimed to evaluate and compare the pharmacokinetic profile of AQUATURM®, a novel, water-soluble curcumin formulation, with that of a widely available commercial curcumin supplement. Methods: A randomized, double-blind, two-period crossover study was conducted in 12 healthy adult participants (6 male, 6 female; aged 20-45 years). Each participant received a single oral dose of either AQUATURM® or the comparator product, followed by a 7-day washout period before receiving the alternate treatment. Blood samples were collected at multiple time points over a 12-h period post-dosing. Plasma curcumin concentrations were quantified using ultra-performance liquid chromatography with tandem mass spectrometry (UPLC-MS/MS). Results: AQUATURM® achieved a significantly higher systemic exposure compared to the comparator, with a more than 7-fold increase in area under the curve (AUC0-12h) and higher peak plasma concentrations (Cmax). AQUATURM® also maintained detectable curcumin levels for the full 12-h observation period, whereas levels from the comparator fell below quantification limits in most participants after 4 h. Conclusions: AQUATURM® significantly enhances curcumin bioavailability in humans compared to a standard curcumin formulation. These pharmacokinetic improvements support its potential for greater clinical efficacy and warrant further evaluation in therapeutic setting.Background/Objectives: Curcumin, the principal bioactive component of Curcuma longa, is known for its anti-inflammatory, antioxidant, and neuroprotective properties. Despite its therapeutic potential, curcumin exhibits poor oral bioavailability due to low solubility, rapid metabolism, and limited gastrointestinal absorption. Various delivery systems have been developed to overcome these limitations. This study aimed to evaluate and compare the pharmacokinetic profile of AQUATURM®, a novel, water-soluble curcumin formulation, with that of a widely available commercial curcumin supplement. Methods: A randomized, double-blind, two-period crossover study was conducted in 12 healthy adult participants (6 male, 6 female; aged 20-45 years). Each participant received a single oral dose of either AQUATURM® or the comparator product, followed by a 7-day washout period before receiving the alternate treatment. Blood samples were collected at multiple time points over a 12-h period post-dosing. Plasma curcumin concentrations were quantified using ultra-performance liquid chromatography with tandem mass spectrometry (UPLC-MS/MS). Results: AQUATURM® achieved a significantly higher systemic exposure compared to the comparator, with a more than 7-fold increase in area under the curve (AUC0-12h) and higher peak plasma concentrations (Cmax). AQUATURM® also maintained detectable curcumin levels for the full 12-h observation period, whereas levels from the comparator fell below quantification limits in most participants after 4 h. Conclusions: AQUATURM® significantly enhances curcumin bioavailability in humans compared to a standard curcumin formulation. These pharmacokinetic improvements support its potential for greater clinical efficacy and warrant further evaluation in therapeutic setting. Curcumin, the principal bioactive component of Curcuma longa, is known for its anti-inflammatory, antioxidant, and neuroprotective properties. Despite its therapeutic potential, curcumin exhibits poor oral bioavailability due to low solubility, rapid metabolism, and limited gastrointestinal absorption. Various delivery systems have been developed to overcome these limitations. This study aimed to evaluate and compare the pharmacokinetic profile of AQUATURM®, a novel, water-soluble curcumin formulation, with that of a widely available commercial curcumin supplement. A randomized, double-blind, two-period crossover study was conducted in 12 healthy adult participants (6 male, 6 female; aged 20-45 years). Each participant received a single oral dose of either AQUATURM® or the comparator product, followed by a 7-day washout period before receiving the alternate treatment. Blood samples were collected at multiple time points over a 12-h period post-dosing. Plasma curcumin concentrations were quantified using ultra-performance liquid chromatography with tandem mass spectrometry (UPLC-MS/MS). AQUATURM® achieved a significantly higher systemic exposure compared to the comparator, with a more than 7-fold increase in area under the curve (AUC h) and higher peak plasma concentrations (Cmax). AQUATURM® also maintained detectable curcumin levels for the full 12-h observation period, whereas levels from the comparator fell below quantification limits in most participants after 4 h. AQUATURM® significantly enhances curcumin bioavailability in humans compared to a standard curcumin formulation. These pharmacokinetic improvements support its potential for greater clinical efficacy and warrant further evaluation in therapeutic setting. |
| Audience | Academic |
| Author | Mahns, David Gyengesi, Erika Mikhael, Meena Niedermayer, Garry Münch, Gerald Pandey, Rishi Jabur, Lillian |
| AuthorAffiliation | 2 Mass Spectrometry Facility, Western Sydney University, Campbelltown, NSW 2560, Australia; r.pandey@westernsydney.edu.au (R.P.); m.mikhael@westernsydney.edu.au (M.M.) 1 Pharmacology Unit, School of Medicine, Western Sydney University, Campbelltown, NSW 2560, Australia; l.jabur@westernsydney.edu.au (L.J.); e.gyengesi@westernsydney.edu.au (E.G.); d.mahns@westernsydney.edu.au (D.M.) 3 School of Science and Health, Western Sydney University, Campbelltown, NSW 2560, Australia; g.niedermayer@westernsydney.edu.au 4 NICM Health Research Institute, Western Sydney University, Campbelltown, NSW 2560, Australia |
| AuthorAffiliation_xml | – name: 4 NICM Health Research Institute, Western Sydney University, Campbelltown, NSW 2560, Australia – name: 2 Mass Spectrometry Facility, Western Sydney University, Campbelltown, NSW 2560, Australia; r.pandey@westernsydney.edu.au (R.P.); m.mikhael@westernsydney.edu.au (M.M.) – name: 1 Pharmacology Unit, School of Medicine, Western Sydney University, Campbelltown, NSW 2560, Australia; l.jabur@westernsydney.edu.au (L.J.); e.gyengesi@westernsydney.edu.au (E.G.); d.mahns@westernsydney.edu.au (D.M.) – name: 3 School of Science and Health, Western Sydney University, Campbelltown, NSW 2560, Australia; g.niedermayer@westernsydney.edu.au |
| Author_xml | – sequence: 1 givenname: Lillian surname: Jabur fullname: Jabur, Lillian – sequence: 2 givenname: Rishi surname: Pandey fullname: Pandey, Rishi – sequence: 3 givenname: Meena surname: Mikhael fullname: Mikhael, Meena – sequence: 4 givenname: Garry surname: Niedermayer fullname: Niedermayer, Garry – sequence: 5 givenname: Erika orcidid: 0000-0001-7371-7385 surname: Gyengesi fullname: Gyengesi, Erika – sequence: 6 givenname: David orcidid: 0000-0003-2131-9638 surname: Mahns fullname: Mahns, David – sequence: 7 givenname: Gerald surname: Münch fullname: Münch, Gerald |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40732360$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkt1u0zAUxyM0xD7ghgdAkbhBaB2248TxFSoVY5OG-FgnLq0T21ldHLvYSaU-EXc8BE-G245tnaZESnL8-_-S45zDbM95p7PsJUYnRcHRu8UM14hhxIon2QGmhI5qQtnevfv97DDGOUIlwxQ_y_ZpYklRoYPs99cZhA6k_2mc7o3Mxw7sKpqY-zbvZzr_YDwswVhojDX9al0ef7saT6--f_775ziH_Af0OowuvR0aq_PJEOTQGZef-tANFnrj3XGenie-W0Aw0bu89yk28W6p3XoZ7F1qCknSbwJnQwcuvxyauZZ9fJ49bcFG_eLmepRdnX6cTs5GF18-nU_GFyNZUtKPGlYpQFVFNS-lUqxp64ISYKxlSrW1UrpggJAiJVUl0qglNcFtXZe8kBiwLo6y861XeZiLRTAdhJXwYMSm4MO1gJD2yWoBnFSIthzxklHSlLWuGw5IEswxVLJNrvdb12JoOq1kajeA3ZHurjgzE9d-KTAhvOaUJ8ObG0PwvwYde9GZKLW14LQfokg_kTJESYUT-voBOvdDSJu7odLJyUZ4Q11D6sC41qcXy7VUjGvKOSOoXLtOHqHSoXRnZBq-1qT6TuDV_U5vW_w_Zwl4uwVk8DEG3d4iGIn1EIu7IU4wegBL028mKX2GsY9F_gG9N_P5 |
| CitedBy_id | crossref_primary_10_1007_s00044_025_03472_8 |
| Cites_doi | 10.1155/2023/2252213 10.3389/fnins.2020.00170 10.1002/mnfr.201901037 10.1016/j.nbd.2018.11.026 10.1002/asia.202400380 10.1021/np1007262 10.1007/s00204-017-1939-4 10.1007/s00394-016-1376-9 10.4103/1673-5374.162686 10.1016/j.fct.2015.05.022 10.1007/s11064-021-03499-4 10.1007/BF03190201 10.1111/j.1600-0773.1978.tb02240.x 10.1016/j.neuint.2015.10.011 10.1186/1475-2891-13-11 10.1111/bph.12131 10.3390/antiox12020393 10.3389/fopht.2023.1205542 10.1038/s41598-020-58838-2 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2025 MDPI AG 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2025 by the authors. 2025 |
| Copyright_xml | – notice: COPYRIGHT 2025 MDPI AG – notice: 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2025 by the authors. 2025 |
| DBID | AAYXX CITATION NPM 3V. 7XB 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU DWQXO GNUQQ GUQSH M2O MBDVC PHGZM PHGZT PIMPY PKEHL PQEST PQQKQ PQUKI PRINS Q9U 7X8 5PM DOA |
| DOI | 10.3390/ph18071073 |
| DatabaseName | CrossRef PubMed ProQuest Central (Corporate) ProQuest Central (purchase pre-March 2016) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central ProQuest Central Student ProQuest Research Library Research Library Research Library (Corporate) ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database Research Library Prep ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Basic ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Central (Alumni Edition) ProQuest One Community College Research Library (Alumni Edition) ProQuest Central China ProQuest Central ProQuest One Academic UKI Edition ProQuest Central Korea ProQuest Research Library ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | CrossRef Publicly Available Content Database MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1424-8247 |
| ExternalDocumentID | oai_doaj_org_article_a92604f9095742b58e8b9a0c2191a6cf PMC12298949 A849972051 40732360 10_3390_ph18071073 |
| Genre | Journal Article |
| GeographicLocations | Australia |
| GeographicLocations_xml | – name: Australia |
| GrantInformation_xml | – fundername: Western Sydney University grantid: PhD scholarship – fundername: Lodaat Pharma grantid: Industry Grant – fundername: Ainsworth MRFF – fundername: LODAAT Pharma – fundername: GRS of Western Sydney University |
| GroupedDBID | --- 2WC 53G 5VS 8G5 AADQD AAFWJ AAYXX ABDBF ABUWG ACGFO ACIHN ACUHS ADBBV AEAQA AFFHD AFKRA AFPKN AFZYC ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BCNDV BENPR BPHCQ CCPQU CITATION DIK DWQXO EBD ESX GNUQQ GROUPED_DOAJ GUQSH GX1 HH5 HYE IAO IHR ITC KQ8 M2O M48 MK0 MODMG M~E OK1 P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC RPM TUS NPM 3V. 7XB 8FK MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c542t-b76da0664e95cdd7bf8342a77f7ddf8dde37a00d254d50e0f2821f88593c1a1e3 |
| IEDL.DBID | BENPR |
| ISICitedReferencesCount | 2 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001539932700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1424-8247 |
| IngestDate | Fri Oct 03 12:51:40 EDT 2025 Tue Nov 04 02:03:18 EST 2025 Thu Oct 02 22:14:45 EDT 2025 Fri Jul 25 18:48:08 EDT 2025 Tue Nov 11 10:46:20 EST 2025 Tue Nov 04 18:12:51 EST 2025 Sun Aug 03 01:53:25 EDT 2025 Tue Nov 18 21:41:52 EST 2025 Sat Nov 29 07:18:23 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Keywords | water-soluble curcumin pharmacokinetics curcuminoids area under the curve plasma bioavailability |
| Language | English |
| License | Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c542t-b76da0664e95cdd7bf8342a77f7ddf8dde37a00d254d50e0f2821f88593c1a1e3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0003-2131-9638 0000-0001-7371-7385 |
| OpenAccessLink | https://www.proquest.com/docview/3233239249?pq-origsite=%requestingapplication% |
| PMID | 40732360 |
| PQID | 3233239249 |
| PQPubID | 2032350 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_a92604f9095742b58e8b9a0c2191a6cf pubmedcentral_primary_oai_pubmedcentral_nih_gov_12298949 proquest_miscellaneous_3234704261 proquest_journals_3233239249 gale_infotracmisc_A849972051 gale_infotracacademiconefile_A849972051 pubmed_primary_40732360 crossref_primary_10_3390_ph18071073 crossref_citationtrail_10_3390_ph18071073 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-07-21 |
| PublicationDateYYYYMMDD | 2025-07-21 |
| PublicationDate_xml | – month: 07 year: 2025 text: 2025-07-21 day: 21 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland – name: Basel |
| PublicationTitle | Pharmaceuticals (Basel, Switzerland) |
| PublicationTitleAlternate | Pharmaceuticals (Basel) |
| PublicationYear | 2025 |
| Publisher | MDPI AG MDPI |
| Publisher_xml | – name: MDPI AG – name: MDPI |
| References | Aggarwal (ref_7) 2013; 169 Ullah (ref_14) 2017; 91 Sharman (ref_5) 2019; 124 Wahlstrom (ref_8) 1978; 43 Lowery (ref_19) 2014; 13 Vieira (ref_18) 2023; 2023 Venigalla (ref_3) 2016; 95 Ullah (ref_11) 2022; 47 Dong (ref_2) 2024; 22 ref_13 ref_12 Purpura (ref_15) 2018; 57 ref_10 Steinijans (ref_17) 1990; 15 Venigalla (ref_4) 2015; 10 Ghosh (ref_6) 2015; 83 ref_9 Sudarshan (ref_1) 2024; 19 Luis (ref_16) 2020; 64 Cuomo (ref_20) 2011; 74 |
| References_xml | – volume: 2023 start-page: 2252213 year: 2023 ident: ref_18 article-title: Impacts of curcumin treatment on experimental sepsis: A systematic review publication-title: Oxidative Med. Cell. Longev. doi: 10.1155/2023/2252213 – ident: ref_12 doi: 10.3389/fnins.2020.00170 – volume: 64 start-page: e1901037 year: 2020 ident: ref_16 article-title: Incomplete hydrolysis of curcumin conjugates by β-glucuronidase: Detection of complex conjugates in plasma publication-title: Mol. Nutr. Food Res. doi: 10.1002/mnfr.201901037 – volume: 124 start-page: 505 year: 2019 ident: ref_5 article-title: Assessment of diets containing curcumin, epigallocatechin-3-gallate, docosahexaenoic acid and alpha-lipoic acid on amyloid load and inflammation in a male transgenic mouse model of Alzheimer’s disease: Are combinations more effective? publication-title: Neurobiol. Dis. doi: 10.1016/j.nbd.2018.11.026 – volume: 19 start-page: e202400380 year: 2024 ident: ref_1 article-title: Recent Advances in the Synthesis of Diarylheptanoids publication-title: Chem. Asian J. doi: 10.1002/asia.202400380 – volume: 74 start-page: 664 year: 2011 ident: ref_20 article-title: Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation publication-title: J. Nat. Prod. doi: 10.1021/np1007262 – volume: 91 start-page: 1623 year: 2017 ident: ref_14 article-title: High bioavailability curcumin: An anti-inflammatory and neurosupportive bioactive nutrient for neurodegenerative diseases characterized by chronic neuroinflammation publication-title: Arch. Toxicol. doi: 10.1007/s00204-017-1939-4 – volume: 57 start-page: 929 year: 2018 ident: ref_15 article-title: Analysis of different innovative formulations of curcumin for improved relative oral bioavailability in human subjects publication-title: Eur. J. Nutr. doi: 10.1007/s00394-016-1376-9 – volume: 10 start-page: 1181 year: 2015 ident: ref_4 article-title: Curcumin and apigenin—Novel and promising therapeutics against chronic neuroinflammation in Alzheimer’s disease publication-title: Neural Regen. Res. doi: 10.4103/1673-5374.162686 – volume: 83 start-page: 111 year: 2015 ident: ref_6 article-title: The beneficial role of curcumin on inflammation, diabetes and neurodegenerative disease: A recent update publication-title: Food Chem. Toxicol. doi: 10.1016/j.fct.2015.05.022 – volume: 47 start-page: 813 year: 2022 ident: ref_11 article-title: The effects of modified curcumin preparations on glial morphology in aging and neuroinflammation publication-title: Neurochem. Res. doi: 10.1007/s11064-021-03499-4 – volume: 22 start-page: 929 year: 2024 ident: ref_2 article-title: Four new diarylheptanoids and two new terpenoids from the fruits of Alpinia oxyphylla and their anti-inflammatory activities publication-title: Chin. J. Nat. Med. – volume: 15 start-page: 173 year: 1990 ident: ref_17 article-title: Pharmacokinetic characterization of controlled-release formulations publication-title: Eur. J. Drug Metab. Pharmacokinet. doi: 10.1007/BF03190201 – volume: 43 start-page: 86 year: 1978 ident: ref_8 article-title: A study on the fate of curcumin in the rat publication-title: Acta Pharmacol. Toxicol. doi: 10.1111/j.1600-0773.1978.tb02240.x – volume: 95 start-page: 63 year: 2016 ident: ref_3 article-title: Novel promising therapeutics against chronic neuroinflammation and neurodegeneration in Alzheimer’s disease publication-title: Neurochem. Int. doi: 10.1016/j.neuint.2015.10.011 – volume: 13 start-page: 11 year: 2014 ident: ref_19 article-title: Comparative absorption of curcumin formulations publication-title: Nutr. J. doi: 10.1186/1475-2891-13-11 – volume: 169 start-page: 1672 year: 2013 ident: ref_7 article-title: Curcumin: An orally bioavailable blocker of TNF and other pro-inflammatory biomarkers publication-title: Br. J. Pharmacol. doi: 10.1111/bph.12131 – ident: ref_9 doi: 10.3390/antiox12020393 – ident: ref_10 doi: 10.3389/fopht.2023.1205542 – ident: ref_13 doi: 10.1038/s41598-020-58838-2 |
| SSID | ssj0057141 |
| Score | 2.3834293 |
| Snippet | Background/Objectives: Curcumin, the principal bioactive component of Curcuma longa, is known for its anti-inflammatory, antioxidant, and neuroprotective... Curcumin, the principal bioactive component of Curcuma longa, is known for its anti-inflammatory, antioxidant, and neuroprotective properties. Despite its... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 1073 |
| SubjectTerms | area under the curve Bioavailability Chemical properties curcuminoids Design Dietary supplements Drug dosages Human subjects Metabolism Metabolites Pharmaceutical research Pharmacokinetics Physiological aspects Plasma Purpura Turmeric water-soluble curcumin |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1fi9QwEA9y-OCL-N_qKRHlRNhyaZM26ePe4uKDHovs6b2VNEm54toeu92D_US--SH8ZM70325R8EXoS5sJNJnJZH5t5jeEvMGsszjjzFeBs77gIvJ1IrGIgLPOxLHlDePNl4_y_FxdXiaLg1JfeCaspQduJ-5UJxBxizyBUABQXBYpp7JEMwMrLdCxydH7Mpn0YKr1wZEMRNCSkXIA9afXV4HCvVTy0fbTsPT_6YsPNqPxQcmDnWd-j9ztQkY6bV_1PrnlygfkZNFyTu8mdLlPodpM6Ald7Nmodw_Jj_72G8STIEJ7GhJa5RSiP3pWVPpGF6uWsHuHj6cQ5y4vPn_69XNCNf0K4ejax-9n2crR2XZttt-Lks4h2u1qf00o3M-Gioa0rqDb7OA8-77XElO16qZD8_-AgufCT0GbR-Ri_n45--B31Rl8E4mw9jMZWw0Bi3BJZKyVWa64CLWUubQ2V-A2udSMWUCgNmKO5QDuglwhv5oJdOD4Y3JUVqV7SiizPFNJ6IRJrIidVuA04kg6APqod-aRd73SUtNRl2MFjVUKEAYVnO4V7JHXg-x1S9jxV6kz1P0ggSTbzQMwvbQzvfRfpueRt2g5KboCeB2ju4wGGBSSaqVTJTAtGdyeR45HkrCEzbi5t720cyGblIccLoTHHnk1NGNPPBZXumrbyAjZoGCPPGlNdRgSIHVojmHy1MiIR2Met5TFVUMwHoQNL3_y7H_M0nNyJ8SayUz6YXBMjur11r0gt81NXWzWL5tl-xvm-Uld priority: 102 providerName: Directory of Open Access Journals |
| Title | Pharmacokinetic Analysis of the Bioavailability of AQUATURM®, a Water-Soluble Curcumin Formulation, in Comparison to a Conventional Curcumin Tablet, in Human Subjects |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/40732360 https://www.proquest.com/docview/3233239249 https://www.proquest.com/docview/3234704261 https://pubmed.ncbi.nlm.nih.gov/PMC12298949 https://doaj.org/article/a92604f9095742b58e8b9a0c2191a6cf |
| Volume | 18 |
| WOSCitedRecordID | wos001539932700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1424-8247 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0057141 issn: 1424-8247 databaseCode: DOA dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1424-8247 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0057141 issn: 1424-8247 databaseCode: M~E dateStart: 20040101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1424-8247 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0057141 issn: 1424-8247 databaseCode: BENPR dateStart: 20040101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1424-8247 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0057141 issn: 1424-8247 databaseCode: PIMPY dateStart: 20040101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVPQU databaseName: Research Library customDbUrl: eissn: 1424-8247 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0057141 issn: 1424-8247 databaseCode: M2O dateStart: 20040101 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lj9MwELbYXQ5ceLMElsoItAip0ebhxM4JtdVWINESrbpQTpFjO2xFaUofK_UXceNH8MuYyaNtBOKCFEWKPZbsZPzNjGN_Q8hLPHUWpr5jC9dom_kssGXEMYmA0UaFofYLxpuP7_lwKMbjKK4W3JbVtsoaEwug1rnCNfIz3_Phwmjhzfy7jVmj8O9qlULjgBwhUxno-VH3fBhf1FgccJe5JSmpD8H92fzKFWhTud8wQwVb_5-YvGeUmhsm9yxQ_87_9v0uuV35nrRTKss9csPM7pPTuCSv3rTpaHcWa9mmpzTe0VpvHpAf9eNXcExBhNZ8JjTPKLiRtDvJ5bWcTEvm7w0Wd8BhHl1eDH79bFNJP4Ffu7BxIS6dGtpbL9T622RG--A2V0nE2hSee9vUiHSVQ7Pe3sb4XasRnvlaFQ2KHxEUIBDXlJYPyWX_fNR7a1dpHmwVMG9lpzzUEjwfZqJAac3TTPjMk5xnXOtMAP76XDqOhlBWB45xMogS3UwgUZtypWv8R-Rwls_MY0Id7aci8gxTkWahkQLQJwy4MSl8_ShwLPK6_uqJqjjQMRXHNIFYCDUk2WmIRV5sZecl88dfpbqoPFsJZOsuCvLFl6Sa_ImMIGpkGXaBMy8NhBFpJB0F1sKVocos8gpVL0FMge4oWR2NgEEhO1fSEQzPNwN-WuSkIQlYoJrVtQImFRYtk532WeT5thpb4v66mcnXhQzjRThtkeNS17dDgpAfqkN4eaIxCxpjbtbMJlcFU7nrFQT_0ZN_9-spueVhWmWH2557Qg5Xi7V5Rm6q69VkuWiRAz4WrWpmt4pFE7gPvA9QFr8bxJ9_AwggXdA |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lj9MwELaWLhJceD8KCxgBi5AabRI7cXJAqFtYbbVtVaEuLKfg2A5bUZrSx6L-Im77I_hlzOTRNgJx2wNSLonHke2Mv_E4nm8IeY5RZ37MbCtwjLY4454lQ4FJBIw2yvc1yxhvPnRErxecnIT9LXJexsLgscoSEzOg1qnCPfI95jK40Ft4M_luYdYo_LtaptDI1eLILH-AyzZ73X4L3_eF6x68G7QOrSKrgKU87s6tWPhagqHlJvSU1iJOAsZdKUQitE4CmO5MSNvW4DlpzzZ2Ak6JkwTIC6Yc6RgG771Etjkqe41s99vd_qcS-z3hcCcnQWUstPcmp06ANlywitnLsgP8aQM2jGD1gOaGxTu4_r-N1Q1yrVhb02Y-GW6SLTO-RXb7OTn3skEH61izWYPu0v6atnt5m_wsb7_CwhtEaMnXQtOEwjKZ7g9TeSaHo5zZfImPm-AQDI7fd3-dN6ikH2HdPrVwozEeGdpaTNXi23BMD8AtKJKkNSjct1apH-k8hWqtjYP_61oDjGmbZxWyHy0UIB73zGZ3yPGFDOJdUhunY3OfUFuzOAhdw1WouW9kAOjqe8KYGLQt9Ow6eVVqWaQKjndMNTKKwNdDjYzWGlknz1ayk5zZ5K9S-6isKwlkI88epNMvUQFukQzBK-YJNkFwN_YCE8ShtBVYQ0f6KqmTl6jqEWImNEfJIvQDOoXsY1Ez4Bi_DfahTnYqkoB1qlpcKnxUYO0sWmt7nTxdFWNNPD84Nukik-Ei2y6ok3v53Fp1iUM3XebD4AWVWVfpc7VkPDzNmNgdN0tgED74d7uekCuHg24n6rR7Rw_JVRdTSNvCcp0dUptPF-YRuazO5sPZ9HGBJ5R8vuhp-Rt8OLdZ |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lj9MwELaWLkJceD8KCxgBi5AaNYmdODkg1O1SUe1uVaEuLKfg2A5bUZrSx6L-Im78AI78MmbyaBuBuO0BKZfE48h25ul4viHkKWad-TGzrcAx2uKMe5YMBRYRMNoo39csQ7x5dyh6veDkJOxvkZ9lLgweqyx1Yqaodapwj7zJXAYXRgvNpDgW0d_vvJp8tbCCFP5pLctp5CxyYJbfIHybvezuw7d-5rqd14P2G6uoMGApj7tzKxa-lmB0uQk9pbWIk4BxVwqRCK2TAESfCWnbGqIo7dnGTiBAcZIAMcKUIx3D4L0XyDa45Nytke1-96j_obQDnnC4kwOiMhbazcmpE6A9F6xiArNKAX_agw2DWD2suWH9Olf_53W7Rq4UPjdt5UJynWyZ8Q2y289Bu5cNOljnoM0adJf213Dey5vke3n7GRxyIKEljgtNEwruM90bpvJMDkc54vkSH7cgUBgcvz369aNBJX0P_vzUwg3IeGRoezFViy_DMe1AuFAUT2tQuG-vSkLSeQrd2hsJAeteA8x1m2cdsh8wFFQ_7qXNbpHjc1nE26Q2TsfmLqG2ZnEQuoarUHPfyAC0ru8JY2LgvNCz6-RFyXGRKrDfsQTJKIIYELkzWnNnnTxZ0U5yxJO_Uu0h464oEKU8e5BOP0WF0otkCNEyT3AIICCxF5ggDqWtwEo60ldJnTxHto9Ql8JwlCxSQmBSiEoWtQKOed1gN-pkp0IJOlBVm0vmjwodPIvWnF8nj1fN2BPPFY5NushouMi2EerkTi5nqylxmKbLfFi8oCKBlTlXW8bD0wyh3XGzwgbhvX-P6xG5BLIYHXZ7B_fJZRcrS9vCcp0dUptPF-YBuajO5sPZ9GGhWij5eN5S-RtWdsAZ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pharmacokinetic+Analysis+of+the+Bioavailability+of+AQUATURM+%C2%AE+%2C+a+Water-Soluble+Curcumin+Formulation%2C+in+Comparison+to+a+Conventional+Curcumin+Tablet%2C+in+Human+Subjects&rft.jtitle=Pharmaceuticals+%28Basel%2C+Switzerland%29&rft.au=Jabur%2C+Lillian&rft.au=Pandey%2C+Rishi&rft.au=Mikhael%2C+Meena&rft.au=Niedermayer%2C+Garry&rft.date=2025-07-21&rft.issn=1424-8247&rft.eissn=1424-8247&rft.volume=18&rft.issue=7&rft_id=info:doi/10.3390%2Fph18071073&rft_id=info%3Apmid%2F40732360&rft.externalDocID=40732360 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1424-8247&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1424-8247&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1424-8247&client=summon |